AI assistant
Roivant Sciences Ltd. — Director's Dealing 2023
Jun 14, 2023
30587_dirs_2023-06-13_71b159b2-e0f3-44fe-a934-e4e8e14c9a25.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Roivant Sciences Ltd. (ROIV)
CIK: 0001635088
Period of Report: 2023-06-09
Reporting Person: Kumar Rakhi (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-09 | Common Shares | M | 43893 | $5.12 | Acquired | 242475 | Direct |
| 2023-06-09 | Common Shares | S | 43893 | $9.93 | Disposed | 198582 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-09 | Stock Option (Right to Buy) | $5.12 | M | 43893 | Disposed | 2025-12-29 | Common Shares (43893) | Direct |
Footnotes
F1: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range set forth in this footnote (1) to this Form 4. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on February 25, 2023.
F2: Award of stock options to purchase Common Shares with a vesting commencement date of December 30, 2015. The award of stock options is fully vested.